Saturday 17 October 2026
Export JANX’s income statement to Excel — free account
Janux Therapeutics, Inc.
JANX Healthcare Biotechnology
Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024. In the quarter to June 2026, revenue grew 2,238.7%, EPS grew 36.4% and free cash flow grew 150.6%, each against the same quarter a year earlier.
16.49
0.83
−4.79%
Follow JANX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 4 | 4 | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Altman Z-Score |
11.61 | 45.12 | 7.69 | 7.61 | 21.34 | — | — | — |
P/S ratio |
44.23 | 271.80 | 60.01 | 67.51 | 127.65 | — | — | — |
Altman Z″-Score (non-manufacturers) |
26.48 | 32.65 | 13.09 | 11.25 | 33.80 | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
P/Operating CF |
(29.96) | (172.07) | (48.99) | (48.80) | (44.29) | — | — | — |
P/B ratio |
0.89 | 2.81 | 1.41 | 1.81 | 1.27 | — | — | — |
Price to Tangible BV |
0.89 | 2.81 | 1.41 | 1.81 | 1.27 | — | — | — |
EV/Sales |
(5.76) | 174.98 | 17.45 | 29.54 | 24.55 | — | — | — |
EV/EBITDA |
0.64 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
EV/Operating CF |
1.35 | (42.29) | (2.79) | (5.93) | (5.26) | — | — | — |
EV/FCF |
1.34 | (41.94) | (2.69) | (5.15) | (4.84) | — | — | — |
Quick Ratio |
38.67 | 58.72 | 26.40 | 19.81 | 29.30 | 4.97 | 0.14 | — |
Current Ratio |
39.04 | 59.21 | 26.80 | 20.14 | 29.46 | 5.05 | 0.14 | — |
Net Debt/EBITDA |
5.58 | 9.55 | 4.37 | 4.78 | 11.37 | 1.62 | 0.17 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.72 | 0.64 | 0.87 | 0.68 | 0.52 | 0.64 | 0.96 | — |
Capex/Depreciation |
0.07 | 0.04 | 0.32 | 4.80 | 25.12 | 0.00 | 0.00 | — |
Interest Coverage |
— | — | — | (16.64) | (128.13) | (23.51) | (16.18) | — |
| (11.48%) | (10.09%) | (17.53%) | (18.36%) | (18.58%) | 60.08% | 35.46% | — | |
| (11.02%) | (9.57%) | (15.66%) | (16.96%) | (16.50%) | (80.30%) | (1,179.38%) | — | |
ROIC |
0.00% | 0.00% | (14,209.31%) | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(11.90%) | (6.76%) | (16.98%) | (19.52%) | (8.94%) | (52.04%) | 101.42% | — |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Research and Development Expense of Revenue |
1,258.96% | 645.90% | 679.48% | 620.54% | 721.39% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
417.71% | 387.67% | 323.39% | 258.50% | 284.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
402.21% | 311.86% | 247.49% | 199.76% | 189.99% | 0.00% | 0.00% | — |
Graham Net Nets |
1.09 | 0.35 | 0.65 | 0.50 | 0.78 | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Earnings Yield |
(13.26%) | (2.39%) | (12.16%) | (10.84%) | (16.55%) | — | — | — |
Free Cash Flow Yield |
(9.74%) | (1.53%) | (10.81%) | (8.49%) | (3.98%) | — | — | — |
Revenue per Share |
0.16 | 0.20 | 0.18 | 0.21 | 0.15 | 0.00 | 0.00 | — |
Operating CF per Share |
(1.33) | (0.82) | (1.15) | (1.03) | (0.72) | (4.77) | (5.72) | — |
Capex per Share |
(0.02) | (0.01) | (0.04) | (0.16) | (0.06) | 0.00 | 0.00 | — |
Free Cash Flow per Share |
(1.34) | (0.82) | (1.19) | (1.19) | (0.78) | (4.77) | (5.72) | — |
Cash per Share |
15.60 | 19.07 | 7.82 | 7.89 | 15.94 | 8.54 | 0.98 | — |
Shareholders Equity per Share |
15.44 | 19.03 | 7.82 | 7.73 | 15.57 | 7.63 | (5.90) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
15.44 | 19.03 | 7.82 | 7.73 | 15.57 | 7.63 | (5.90) | — |
Free Cash Flow |
(83.28) | (44.17) | (52.42) | (49.37) | (18.46) | (4.37) | (3.83) | — |
Working Capital |
950.89 | 1,016.21 | 336.21 | 315.93 | 364.22 | 12.88 | (3.97) | — |
Capital Expenditures |
(1.04) | (0.36) | (1.85) | (6.44) | (1.48) | — | — | — |
Net Current Asset Value |
931.14 | 994.93 | 313.18 | 289.17 | 363.52 | 6.83 | (3.97) | — |
EV/EBIT |
0.71 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Capex to Sales |
0.10 | 0.03 | 0.23 | 0.75 | 0.41 | — | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
(4.04) | (1.75) | (0.82) | (0.19) | (0.04) | 0.08 | 0.29 | — |
Cash ROIC |
(4.33%) | (2.16%) | (7.62%) | (7.62%) | (2.49%) | (29.52%) | 116.35% | — |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 19.14 | 0.89 | 0.00 | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
— | — | — | 0.45 | 4.10 | 4.10 | — | — |
Average Payables |
4.50 | 3.23 | 2.29 | 2.31 | 1.44 | 0.35 | 0.35 | — |
Average Assets |
1,031.54 | 720.96 | 372.21 | 371.92 | 198.02 | 8.45 | 0.34 | — |
Average Common Equity |
989.80 | 683.57 | 332.54 | 343.53 | 175.84 | (11.29) | (11.29) | — |
Columns are period end dates